Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022 at 8:00 AM ET.
In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the fireside chat will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com. The webcast replay will be available approximately two hours after the event and will be archived for 90 days.
About Corbus
Corbus is an immunology company committed to connecting innovation to our purpose of improving lives by developing new medicines that target the nexus between the immune system and cancer. Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
INVESTOR CONTACT:
Brian Walsh, VP, Corporate Development
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +1 (781) 264 8944
| Last Trade: | US$19.51 |
| Daily Change: | -32.19 -62.26 |
| Daily Volume: | 12,174,945 |
| Market Cap: | US$234.900M |
August 20, 2024 August 06, 2024 May 30, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
